Practical considerations in the management of patients treated with bosutinib for chronic myeloid leukemia
Annals of Hematology · 2024-09 · 103 (9) · 3429-3442
DOI: 10.1007/s00277-024-05851-4 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Annals of Hematology, online erschienen am 18.07.2024. Verfasst von Jeffrey H Lipton und 4 weiteren Autor:innen. Beteiligte Einrichtung: Princess Margaret Cancer Centre, Toronto, Canada. jeffreyhlipton@gmail.com. Hauptthemen laut MEDLINE: Aniline Compounds, Nitriles, Quinolines, Leukemia, Myelogenous, Chronic, BCR-ABL Positive. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Bosutinib is a second-generation tyrosine kinase inhibitor indicated for the treatment of patients with newly diagnosed Philadelphia chromosome–positive chronic phase chronic myeloid leukemia (CML), and for patients with Ph + chronic phase, accelerated phase, or blast phase CML resistant or intolerant to prior therapy. As is the case for all TKIs approved for treatment of CML, bosutinib is associated with adverse events (AEs) that require appropriate management to ensure adherence to treatment and optimized outcomes. The aim of this review is to provide physicians with updated practical information for the prevention and management of AEs occurring during treatment with bosutinib, including dosing strategies, based on the latest published evidence and clinical experience. Clinical studies and real-world evidence have shown bosutinib has a generally favorable safety profile, which has remained consistent across lines of therapy and in long-term reports. Adjusting the starting dose and/or modifying the dose during treatment with bosutinib are important strategies to manage AEs and improve tolerability, which are recognized within the label and in treatment guidelines. Dosing adjustment strategies to manage AEs are a recognized management approach for other TKIs in the treatment of CML and are not exclusive to bosutinib. In summary, long-term results from clinical trials and emerging real-world evidence demonstrate bosutinib has a safety profile that can largely be managed with treatment modifications and/or supportive care. Increased experience in managing toxicities and by using a personalized dosing approach may further improve adherence and outcomes with bosutinib.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Princess Margaret Cancer Centre, Toronto, Canada. jeffreyhlipton@gmail.com.
- Department of Hematology, Oncology, Hemostaseology and Stem Cell Transplantation, Faculty of Medicine, RWTH Aachen University Hospital, Aachen, Germany.
- Center for Integrated Oncology, Aachen Bonn Cologne Düsseldorf (CIO ABCD), Aachen, Germany.
- Moffitt Cancer Center, Tampa, FL, USA.
- Centre for Haematology, Imperial College London, London, UK.
- Division of Hematology and SCT, Georgia Cancer Center, Augusta, GA, USA.
Zitieren
APA
Lipton, J. H., Brümmendorf, T. H., Sweet, K., Apperley, J. F., & Cortes, J. E. (2024). Practical considerations in the management of patients treated with bosutinib for chronic myeloid leukemia. Annals of Hematology, 103(9), 3429-3442. https://doi.org/10.1007/s00277-024-05851-4
Vancouver
Lipton JH, Brümmendorf TH, Sweet K, Apperley JF, Cortes JE. Practical considerations in the management of patients treated with bosutinib for chronic myeloid leukemia. Annals of Hematology. 2024;103(9):3429-3442. doi:10.1007/s00277-024-05851-4
BibTeX
@article{Lipton2024,
author = {Lipton, Jeffrey H and Brümmendorf, Tim H and Sweet, Kendra and Apperley, Jane F and Cortes, Jorge E},
title = {Practical considerations in the management of patients treated with bosutinib for chronic myeloid leukemia},
journal = {Annals of Hematology},
year = {2024},
volume = {103},
number = {9},
pages = {3429--3442},
doi = {10.1007/s00277-024-05851-4}
}
EUVIMED